<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="860">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01063660</url>
  </required_header>
  <id_info>
    <org_study_id>MC-FludT.7/AML</org_study_id>
    <nct_id>NCT01063660</nct_id>
  </id_info>
  <brief_title>Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)</brief_title>
  <official_title>Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Acute Myeloid Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>medac GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, multinational, non-randomized, non-controlled open-label phase II
      trial to evaluate the safety and efficacy of treosulfan in a combination regimen with
      fludarabine as conditioning therapy prior to allogeneic stem cell transplantation (SCT) in
      patients with AML.

      The aim is to demonstrate a clinical benefit compared with historical data on intravenous
      busulfan (BusulfexTM, BusilvexTM), the only drug so far registered in the indication
      conditioning before allogeneic stem cell transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Efficacy - Evaluation of engraftment. Safety - Evaluation of the incidence of the following CTC grade 3 and 4 adverse events between day -6 and day +28 - hyperbilirubinemia and mucositis / stomatitis - veno-occlusive disease - seizures</measure>
    <time_frame>3.5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Evaluation of disease free survival (DFS) - Evaluation of overall survival (OS) - Evaluation of relapse incidence (RI) - Donor chimerism on day +28, +56 and +100. Safety - Evaluation of NRM on days +28 and +100</measure>
    <time_frame>3.5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Acute Myeloid Leukaemia</condition>
  <arm_group>
    <arm_group_label>Treosulfan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with acute myeloid leukaemia (AML) according to WHO classification (&gt; 20% myeloblasts in peripheral blood or bone marrow at initial diagnosis) with &lt; 5% myeloblasts in the bone marrow, indicated for allogeneic transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>14 g/mÂ²/d day -6 to -4</description>
    <arm_group_label>Treosulfan</arm_group_label>
    <other_name>Ovastat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute myeloid leukaemia (AML) according to WHO classification (&gt; 20%
             myeloblasts in peripheral blood or bone marrow at initial diagnosis) with &lt; 5%
             myeloblast in the bone marrow, indicated for allogeneic transplantation

          -  Availability of an HLA-identical sibling donor (MRD) or HLA-identical unrelated donor
             (MUD) HLA-identity defined by the following markers: A, B, DRB1, DQB1.

          -  Target graft size (unmanipulated)

          -  bone marrow: 2 - 10 x 106 CD34+ cells/kg BW recipient or &gt; 2 x 108 nucleated cells/kg
             BW recipient or

          -  peripheral blood: 4 - 10 x 106 CD34+ cells/kg BW recipient

          -  Age &gt; 18 and &lt; 60 years

          -  Karnofsky Index &gt; 80 %

          -  Adequate contraception in female patients of child-bearing potential

          -  Written informed consent

        Exclusion Criteria:

          -  Therapy related secondary AML

          -  AML with t(8;21)(q22;q22) in CR1

          -  Acute promyelocytic leukaemia with t(15;17)(q22;q12) in CR1

          -  Secondary malignancies

          -  Previous allogeneic transplantation

          -  Severe concomitant illnesses / medical conditions (e.g. impaired respiratory and/or
             cardiac function)

          -  Known and manifested malignant involvement of the CNS

          -  Active infectious disease

          -  HIV- positivity or active hepatitis infection

          -  Impaired liver function (Bilirubin &gt; upper normal limit; Transaminases &gt; 3.0 x upper
             normal limit)

          -  Impaired renal function (Creatinine-clearance &lt; 60 ml/min; Serum Creatinine &gt; 1.5 x
             upper normal limit).

          -  Pleural effusion or ascites &gt; 1.0 L

          -  Pregnancy or lactation

          -  Known hypersensitivity to treosulfan and/or fludarabine

          -  Participation in another experimental drug trial within 4 weeks before day -6

          -  Non-co-operative behaviour or non-compliance

          -  Psychiatric diseases or conditions that might impair the ability to give informed
             consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathias Freund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rostock</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <lastchanged_date>February 4, 2010</lastchanged_date>
  <firstreceived_date>February 3, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Prof. Dr. Mathias Freund</name_title>
    <organization>University of Rostock</organization>
  </responsible_party>
  <keyword>Treosulfan</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>ATG</keyword>
  <keyword>AML</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Treosulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
